Using a modified poliovirus to enhance cancer immunotherapy
Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
This study is exploring how a safe version of the poliovirus can help boost your immune system to better fight cancer by getting special immune cells to work harder at targeting and destroying cancer cells, and you might have the chance to be part of this exciting new treatment approach!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11043500 on NIH RePORTER |
What this research studies
This research investigates how a modified poliovirus can be used to improve the immune system's ability to fight cancer. It focuses on a specific type of immune cell, called dendritic cells, which play a crucial role in presenting tumor antigens to the immune system. By using a safe version of the poliovirus, the study aims to stimulate these dendritic cells to activate other immune cells that can target and destroy cancer cells more effectively. Patients may have the opportunity to contribute to this innovative approach to cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer who may benefit from enhanced immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those who do not have a suitable immune response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that harness the body's immune system to fight tumors.
How similar studies have performed: Previous research has shown promising results using similar viral approaches in cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Gromeier, Matthias — Duke University
- Study coordinator: Gromeier, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.